15 Million Americans Expected to Have Alzheimer's by 2060

This article originally appeared here.
Share this content:
15 Million Americans Expected to Have Alzheimer's by 2060
15 Million Americans Expected to Have Alzheimer's by 2060

THURSDAY, Dec. 7, 2017 (HealthDay News) -- A total of 15.0 million Americans are expected to have clinical Alzheimer's disease (AD) or mild cognitive impairment by 2060, according to a study published online Dec. 7 in Alzheimer's & Dementia.

Ron Brookmeyer, Ph.D., from the University of California in Los Angeles, and colleagues used a multistate model incorporating biomarkers for preclinical AD with projections for the U.S. population to forecast the prevalence of AD.

The researchers note that about 6.08 million Americans had clinical AD or mild cognitive impairment due to AD in 2017. By 2060, this number is expected to increase to 15.0 million. Preclinical AD (amyloidosis, neurodegeneration, or both) was seen in 46.7 million Americans in 2017; many are not expected to progress to clinical disease during their lifetime. A differential impact is anticipated for primary and secondary preventions on future disease burden.

"Because large numbers of persons are living with preclinical AD, our results underscore the need for secondary preventions for persons with existing AD brain pathology who are likely to develop clinical disease during their lifetimes as well as primary preventions for persons without preclinical disease," the authors write.

One author disclosed financial ties to Takeda.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »